Along with MYCN, other proto-oncogenes such as MYC and KRAS up-regulate components of the spliceosome in cancer, indicating a possible addiction to a hyperactivated spliceosome, and a potential novel therapeutic target [21, 27, 28]. This evidence concerns the gene MYC and cancer.